2017

Amplyx appoints Ciara Kennedy president and chief executive officer

Monday, January 9, 2017

Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, has announced the appointments of Ciara Kennedy, Ph.D., to president and chief executive officer (CEO) and Karen Joy Shaw, Ph.D., to chief scientific officer (CSO). In conjunction with this announcement, the company’s former president and CEO, Mike Grey, has assumed the role of executive chairman of the Amplyx board of directors. 

[Read More]

Foundation Medicine appoints Troy Cox CEO

Monday, January 9, 2017

Foundation Medicine has announced that, as part of the succession of its executive leadership, the board of directors has appointed Troy Cox, a highly regarded global biopharma leader, as chief executive officer to succeed Michael Pellini, M.D. Dr. Pellini, who has served as chief executive officer of the company since 2011, has been appointed chairman of the company’s board of directors. Alexis Borisy, founding chief executive officer and current chairman of the board for Foundation Medicine, will continue to serve on the board of directors. Cox will also join the board of directors. All of these changes will become effective by February 6, 2017.

[Read More]

Viriom, NIH partner on Zika and other major viral diseases

Monday, January 9, 2017

Viriom has entered into a collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to identify new drug candidates for treatment of the Zika and other important virus infections. Under the collaboration agreement, Viriom and Dr. Leo Margolis of NICHD will study and improve the antiviral properties of Viriom’s lead compounds against the Zika virus, HBV, HCV, HIV, RSV and other clinically relevant viruses.

[Read More]

Lantern Pharma, Intuition Systems partner in biomarker discovery

Monday, January 9, 2017

Lantern Pharma has reached an agreement to collaborate with India-based AI and data analytics company, Intuition Systems. Lantern Pharma is a privately held, global biotech company pioneering the field of precision oncology. Lantern’s proprietary approach to drug development is driven by advanced genomics and machine learning-based artificial intelligence (AI), which when combined, are advancing a new wave of precision drug therapies that significantly reduce the time to market and overall risk associated with drug development. Intuition will work closely with Lantern’s existing computational team to bring additional AI, big data analysis, cloud support and infrastructure to support drug development and biomarker identification.

[Read More]

Takeda to acquire ARIAD Pharmaceuticals

Monday, January 9, 2017

Takeda Pharmaceutical and ARIAD Pharmaceuticals have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24 per share in cash, or an enterprise value of approximately $5.2 billion. The transaction has been approved unanimously by the boards of directors of both companies, and is expected to close by the end of February 2017, subject to required regulatory approvals and other customary closing conditions. Sarissa Capital, the holder of 6.6% of ARIAD’s common shares, as well as each of the members of ARIAD’s board of directors have agreed to tender their shares to Takeda pursuant to the offer.

[Read More]

Innovus Pharma adds Randy Berholtz as EVP, Corporate Development and General Counsel

Monday, January 9, 2017

Innovus Pharmaceuticals, an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, has announced that Randy Berholtz will join the management team as executive vice president, Corporate Development and General Counsel. A life sciences business and legal veteran with decades of experience, Berholtz joins Innovus Pharma to expand its corporate development efforts to find and enter into additional collaborations to expand the breadth and depth of product offerings on a worldwide basis.

[Read More]

Evotec, Eternygen to develop novel metabolic disease therapy

Monday, January 9, 2017

Evotec will extend its existing relationship with Eternygen by becoming an investor in addition to being a preclinical drug discovery partner. Within a consortium of investors including VC Fonds Technologie Berlin, managed by IBB Beteiligungsgesellschaft mbH, and two renowned family offices, Epidarex and Evotec together will participate in Eternygen’s latest funding round of EUR 8 million (approx. $8.3 million).

[Read More]